정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2095 | Recruiting | Booster Dose Trial | Cancer | Biological: BNT162b2 vaccine | Phase 2 | Montefiore Medical Center, Albert Einstein College of Medicine | OTHER | 100 | All | 18 Years | Montefiore Medical Center, Bronx, New York, United States |
2094 | Active, not recruiting | Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | COVID19 | Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine | Phase 1 | Livzon Pharmaceutical Group Inc., Guangdong Center for Disease Prevention and Control, Simoon Record Pharma Information Consulting Co., Ltd. | INDUSTRY | 43 | All | 18 Years | Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China |
2093 | Recruiting | Booster Vaccination Against SARS-CoV-2 | Sars-CoV-2 Infection | Biological: CoronaVac Biological: Turkovac |
Phase 2 | Health Institutes of Turkey | OTHER_GOV | 222 | All | 18 Years ~ 60 Years | Ankara City Hospital Internal Medicine Clinic, Ankara, Turkey Sancaktepe Martyr Professor Dr. ?lhan Varank Training and Research Hospital Infectious Diseases and Clinical Microbiology Clinic, Istanbul, Turkey T.R. Ministry of Health Kartal Dr. Lutfi Kirdar City Hospital Infectious Diseases, Istanbul, Turkey Umraniye Training and Research Hospital Infectious Diseases, Istanbul, Turkey |
2092 | Recruiting | B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency | Immune Deficiency Disease | Biological: CoVAC-1 | Phase 2 | University Hospital Tuebingen | OTHER | 68 | All | 18 Years | University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany |
2091 | Recruiting | Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2) | Inflammation | Drug: Standardized Brazilian Green Propolis Extract Drug: Placebo |
Phase 3 | D'Or Institute for Research and Education, Apis Flora Industrial e Comercial Ltda | OTHER | 200 | All | 18 Years | Hospital Sao Rafael, Salvador, BA, Brazil |
2090 | Not yet recruiting | Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) | Malaria | Drug: Albendazole Pill Drug: Ivermectin Pill Drug: Ivermectin Injectable Product |
Phase 3 | Barcelona Institute for Global Health, UNITAID | OTHER | 100000 | All | ~ 99 Years | |
2089 | Recruiting | BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization | COVID 19 | Drug: Bromhexine and Spironolactone Drug: Base therapy |
Phase 3 | Lomonosov Moscow State University Medical Research and Educational Center | OTHER | 80 | All | 18 Years | Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation |